
Sign up to save your podcasts
Or


Xlife Sciences CEO Oliver Baumann introduces us to the fund, which is publicly traded in Switzerland, while VERAXA CEO Christoph Antz describes the BiTAC AND-gating platform the company uses to improve on the precision of T-cell engagers and antibody-drug conjugates.
By BiotechTV4.3
66 ratings
Xlife Sciences CEO Oliver Baumann introduces us to the fund, which is publicly traded in Switzerland, while VERAXA CEO Christoph Antz describes the BiTAC AND-gating platform the company uses to improve on the precision of T-cell engagers and antibody-drug conjugates.

3,223 Listeners

1,925 Listeners

124 Listeners

325 Listeners

61 Listeners

9,948 Listeners

86 Listeners

33 Listeners

353 Listeners

19 Listeners

60 Listeners

510 Listeners

41 Listeners

0 Listeners

4 Listeners

2 Listeners

6 Listeners

48 Listeners